{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T01:38:43Z","timestamp":1794620323532,"version":"4.9.1"},"reference-count":72,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Science and Technology Planning Projects of Guizhou Province, and Zunyi City","award":["QKHJC-zk(2025)MS384, gzwkj2023-121, gzwkj2024-103, QZYY-2023-021, and ZSKH-HZ(2024)361"],"award-info":[{"award-number":["QKHJC-zk(2025)MS384, gzwkj2023-121, gzwkj2024-103, QZYY-2023-021, and ZSKH-HZ(2024)361"]}]},{"name":"WBE Liver Fibrosis Foundation","award":["CFHPC2025028"],"award-info":[{"award-number":["CFHPC2025028"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,2]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>\n                      Amyloidosis is a rare, clinically heterogeneous disease, which makes its diagnosis difficult. The relationship between amyloidosis and gene mutations is insufficiently understood. We report a case of sphingosine-1-phosphate lyase 1 (\n                      <jats:italic toggle=\"yes\">SGPL1<\/jats:italic>\n                      ) mutation-related amyloidosis, and review the related literature.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>\n                      A 53-year-old man was admitted to our hospital with a 5-month history of renal dysfunction and abdominal distension, aggravated since 2 days. Five months ago, the patient was diagnosed with nephrotic syndrome, with liver dysfunction and abdominal distension. His symptoms improved after treatment with methylprednisolone sodium succinate, dipyridamole, hydroxychloroquine sulfate, and ursodeoxycholic acid. Two days ago, his abdominal distension worsened, and was not associated with eating, acid reflux, heartburn, fatigue, or poor appetite. A physical examination showed periumbilical ecchymosis and hepatic enlargement. Blood biochemistry showed kidney dysfunction, dyslipidemia, increased alkaline phosphatase and glutamyltransferase, and decreased albumin. A urine protein test was positive. A liver biopsy showed chronic hepatitis and positive Congo red staining. Serum and urine immunofixation electrophoresis showed increased monoclonal IgA-\u03ba protein. Color echocardiography and magnetic resonance imaging showed left ventricular wall thickening and slight pericardial effusion. Sanger sequencing showed a heterozygous, autosomal recessive mutation in the\n                      <jats:italic toggle=\"yes\">SGPL1<\/jats:italic>\n                      gene (blood). In our patient, amyloidosis was attributed to increased monoclonal IGA-\u03ba protein production by plasma cells after\n                      <jats:italic toggle=\"yes\">SGPL1<\/jats:italic>\n                      mutation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnosis:<\/jats:title>\n                    <jats:p>Primary amyloidosis with multisystem involvement (liver, heart, and kidneys).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>The patient was administered dipyridamole (25\u2009mg, po, tid), methylprednisolone (40\u2009mg, po, qd, gradually reduced over 6 months), hydroxychloroquine sulfate (200\u2009mg, po, bid), and ursodeoxycholic acid (250\u2009mg, po, tid) until his renal and hepatic markers improved. Immunomodulatory therapy was adjusted according to the patient\u2019s response, and the final regimen was bortezomib injection (1.8\u2009mg, sc, once a week), cyclophosphamide (0.4\u2009g, po, once a week), and dexamethasone (20\u2009mg, po, twice a week), which is currently ongoing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcome:<\/jats:title>\n                    <jats:p>Immunomodulatory therapy improved and stabilized the patient\u2019s condition.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>\n                      <jats:italic toggle=\"yes\">SGPL1<\/jats:italic>\n                      mutation may cause multisystem amyloidosis by disrupting S1P homeostasis and increasing monoclonal IGA-\u03ba protein production, leading to amyloidosis. This case highlights the importance of genetic screening and an improved understanding of\n                      <jats:italic toggle=\"yes\">SGPL1<\/jats:italic>\n                      gene mutations.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000046653","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T15:03:04Z","timestamp":1767711784000},"page":"e46653","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Diagnosis and treatment of multisystem amyloidosis associated with SGPL1 mutation: A case report and review of the literature"],"prefix":"10.1097","volume":"105","author":[{"given":"Yunfen","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Affiliated Hospital of Zunyi Medical University, `Zunyi, Guizhou Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Liao","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Affiliated Hospital of Zunyi Medical University, `Zunyi, Guizhou Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxia","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Affiliated Hospital of Zunyi Medical University, `Zunyi, Guizhou Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghua","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Affiliated Hospital of Zunyi Medical University, `Zunyi, Guizhou Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Affiliated Hospital of Zunyi Medical University, `Zunyi, Guizhou Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bangneng","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Bozhou District People\u2019s Hospital, Zunyi, Guizhou Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuying","family":"Fan","sequence":"additional","affiliation":[{"name":"Guizhou Provincial Key Laboratory of Cell Engineering, Zunyi, Guizhou Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuedong","family":"Yi","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8639-3436","authenticated-orcid":false,"given":"Yihuai","family":"He","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Affiliated Hospital of Zunyi Medical University, `Zunyi, Guizhou Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8845-1265","authenticated-orcid":false,"given":"Yawen","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Affiliated Hospital of Zunyi Medical University, `Zunyi, Guizhou Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260218","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1016\/S0140-6736(15)01274-X","article-title":"Systemic amyloidosis.","volume":"387","author":"Wechalekar","year":"2016","journal-title":"Lancet"},{"key":"R2-20260218","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1002\/ajh.24433","article-title":"Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment.","volume":"91","author":"Gertz","year":"2016","journal-title":"Am J Hematol"},{"key":"R3-20260218","doi-asserted-by":"crossref","first-page":"e0146614","DOI":"10.1371\/journal.pone.0146614","article-title":"Prognostic significance of KIT mutations in core-binding factor acute myeloid leukemia: a systematic review and meta-analysis.","volume":"11","author":"Chen","year":"2016","journal-title":"PLoS One"},{"key":"R4-20260218","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/modpathol.2017.124","article-title":"Intratubular amyloid in light chain cast nephropathy is a risk factor for systemic light chain amyloidosis.","volume":"31","author":"Gibier","year":"2018","journal-title":"Mod Pathol"},{"key":"R5-20260218","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1212\/WNL.51.3.708","article-title":"Genotypic\u2013phenotypic variations in a series of 65 patients with familial amyloid polyneuropathy.","volume":"51","author":"Plante-Bordeneuve","year":"1998","journal-title":"Neurology"},{"key":"R6-20260218","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41583-021-00533-w","article-title":"The probabilistic model of Alzheimer disease: the amyloid hypothesis revised.","volume":"23","author":"Frisoni","year":"2022","journal-title":"Nat Rev Neurosci"},{"key":"R7-20260218","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1001\/archneur.57.6.885","article-title":"Early-onset Alzheimer disease caused by a new mutation (V717L) in the amyloid precursor protein gene.","volume":"57","author":"Murrell","year":"2000","journal-title":"Arch Neurol"},{"key":"R8-20260218","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41419-017-0252-8","article-title":"Pharmacological activation of autophagy favors the clearing of intracellular aggregates of misfolded prion protein peptide to prevent neuronal death.","volume":"9","author":"Thellung","year":"2018","journal-title":"Cell Death Dis"},{"key":"R9-20260218","doi-asserted-by":"crossref","first-page":"e202400244","DOI":"10.1002\/cmdc.202400244","article-title":"Native state stabilization of amyloidogenic proteins by kinetic stabilizers: inhibition of protein aggregation and clinical relevance.","volume":"19","author":"Priyanka","year":"2024","journal-title":"ChemMedChem"},{"key":"R10-20260218","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.3892\/ol.2017.5767","article-title":"Flow cytometry-based immunophenotypic analysis of primary systemic light chain amyloidosis.","volume":"13","author":"Diao","year":"2017","journal-title":"Oncol Lett"},{"key":"R11-20260218","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1159\/000506498","article-title":"High-dose melphalan and autologous peripheral blood stem cell transplantation in AL amyloidosis.","volume":"143","author":"Sanchorawala","year":"2020","journal-title":"Acta Haematol"},{"key":"R12-20260218","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1741-7015-12-2","article-title":"Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trial.","volume":"12","author":"Huang","year":"2014","journal-title":"BMC Med"},{"key":"R13-20260218","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1200\/JCO.2009.23.8220","article-title":"Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis.","volume":"28","author":"Kastritis","year":"2010","journal-title":"J Clin Oncol"},{"key":"R14-20260218","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.patbio.2014.10.001","article-title":"Successful treatment of renal light chain (AL) amyloidosis with bortezomib and dexamethasone (VD).","volume":"63","author":"Huang","year":"2015","journal-title":"Pathol Biol (Paris)"},{"key":"R15-20260218","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.1200\/JCO.20.01285","article-title":"Bortezomib, melphalan, and dexamethasone for light-chain amyloidosis.","volume":"38","author":"Kastritis","year":"2020","journal-title":"J Clin Oncol"},{"key":"R16-20260218","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1182\/bloodadvances.2019000147","article-title":"Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone.","volume":"3","author":"Kastritis","year":"2019","journal-title":"Blood Adv"},{"key":"R17-20260218","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood.2019004460","article-title":"Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA.","volume":"136","author":"Palladini","year":"2020","journal-title":"Blood"},{"key":"R18-20260218","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1182\/blood.2019004369","article-title":"A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis.","volume":"135","author":"Roussel","year":"2020","journal-title":"Blood"},{"key":"R19-20260218","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/ajcp\/aqad017","article-title":"Differences between kappa and lambda light chain amyloidosis analyzed by a pathologic scoring system.","volume":"160","author":"Wu","year":"2023","journal-title":"Am J Clin Pathol"},{"key":"R20-20260218","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/protein\/gzz012","article-title":"Adaption of human antibody lambda and kappa light chain architectures to CDR repertoires.","volume":"32","author":"van der Kant","year":"2019","journal-title":"Protein Eng Des Sel"},{"key":"R21-20260218","doi-asserted-by":"crossref","first-page":"9531","DOI":"10.3390\/ijms24119531","article-title":"Free light chains kappa and lambda as new biomarkers of selected diseases.","volume":"24","author":"Gudowska-Sawczuk","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R22-20260218","first-page":"4718","article-title":"Plasma cell myeloma with dual expression of kappa and lambda light chains.","volume":"11","author":"Jiang","year":"2018","journal-title":"Int J Clin Exp Pathol"},{"key":"R23-20260218","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1756-8722-4-47","article-title":"Light chain (AL) amyloidosis: update on diagnosis and management.","volume":"4","author":"Rosenzweig","year":"2011","journal-title":"J Hematol Oncol"},{"key":"R24-20260218","doi-asserted-by":"crossref","first-page":"285","DOI":"10.5946\/ce.2017.118","article-title":"Localized gastric amyloidosis with kappa and lambda light chain co-expression.","volume":"51","author":"Ahn","year":"2018","journal-title":"Clin Endosc"},{"key":"R25-20260218","doi-asserted-by":"crossref","first-page":"e247742","DOI":"10.1136\/bcr-2021-247742","article-title":"Oligosecretory myeloma with gastrointestinal tract involvement: an unusual presentation and literature review.","volume":"15","author":"Ling","year":"2022","journal-title":"BMJ Case Rep"},{"key":"R26-20260218","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.2215\/CJN.10491012","article-title":"Renal amyloidosis: origin and clinicopathologic correlations of 474 recent cases.","volume":"8","author":"Said","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"R27-20260218","doi-asserted-by":"crossref","first-page":"5126","DOI":"10.1182\/blood-2010-06-290668","article-title":"Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features.","volume":"116","author":"Kumar","year":"2010","journal-title":"Blood"},{"key":"R28-20260218","doi-asserted-by":"crossref","first-page":"120341","DOI":"10.1016\/j.jns.2022.120341","article-title":"Prevalence and predictors of neurological manifestations in systemic AL amyloidosis.","volume":"440","author":"Thimm","year":"2022","journal-title":"J Neurol Sci"},{"key":"R29-20260218","doi-asserted-by":"crossref","first-page":"bcr2016214392","DOI":"10.1136\/bcr-2016-214392","article-title":"Acute liver failure due to primary amyloidosis in a nephrotic syndrome: a swiftly progressive course.","volume":"2016","author":"Cardoso","year":"2016","journal-title":"BMJ Case Rep"},{"key":"R30-20260218","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.3390\/cells9061553","article-title":"Amyloid proteins and peripheral neuropathy.","volume":"9","author":"Asiri","year":"2020","journal-title":"Cells"},{"key":"R31-20260218","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1515\/cclm-2015-0994","article-title":"Laboratory testing in monoclonal gammopathy of renal significance (MGRS).","volume":"54","author":"Leung","year":"2016","journal-title":"Clin Chem Lab Med"},{"key":"R32-20260218","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.4081\/cp.2019.1146","article-title":"Non-traumatic splenic rupture in amyloidosis as a rare evolution of multiple myeloma.","volume":"9","author":"Perrone","year":"2019","journal-title":"Clin Pract"},{"key":"R33-20260218","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.bpc.2015.07.005","article-title":"Thermodynamic and fibril formation studies of full length immunoglobulin light chain AL-09 and its germline protein using scan rate dependent thermal unfolding.","volume":"207","author":"Blancas-Mejia","year":"2015","journal-title":"Biophys Chem"},{"key":"R34-20260218","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/cmi.2008.36","article-title":"Laboratory characterizations on 2007 cases of monoclonal gammopathies in East China.","volume":"5","author":"Wang","year":"2008","journal-title":"Cell Mol Immunol"},{"key":"R35-20260218","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1172\/JCI89626","article-title":"Mutations in sphingosine-1-phosphate lyase cause nephrosis with ichthyosis and adrenal insufficiency.","volume":"127","author":"Lovric","year":"2017","journal-title":"J Clin Invest"},{"key":"R36-20260218","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s00467-022-05656-5","article-title":"A rare cause of nephrotic syndrome-sphingosine-1-phosphate lyase (SGPL1) deficiency: 6 cases and a review of the literature.","volume":"38","author":"Tastemel Ozturk","year":"2023","journal-title":"Pediatr Nephrol"},{"key":"R37-20260218","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.3390\/ijms24043267","article-title":"Loss of S1P lyase expression in human podocytes causes a reduction in nephrin expression that involves PKCdelta activation.","volume":"24","author":"Imeri","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R38-20260218","first-page":"69","article-title":"Sphingosine-phosphate lyase.","volume":"26","author":"van Veldhoven","year":"1993","journal-title":"Adv Lipid Res"},{"key":"R39-20260218","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/jdv.17764","article-title":"Novel functions of S1P in chronic itchy and inflammatory skin diseases.","volume":"36","author":"Gray","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R40-20260218","doi-asserted-by":"crossref","first-page":"eaav1263","DOI":"10.1126\/sciimmunol.aav1263","article-title":"CD4 T cell sphingosine 1-phosphate receptor (S1PR)1 and S1PR4 and endothelial S1PR2 regulate afferent lymphatic migration.","volume":"4","author":"Xiong","year":"2019","journal-title":"Sci Immunol"},{"key":"R41-20260218","first-page":"809","article-title":"Sphingosine 1-phosphate signaling at the skin barrier interface.","volume":"11","author":"Masuda-Kuroki","year":"2022","journal-title":"Biology (Basel)"},{"key":"R42-20260218","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1212\/WNL.0b013e31820d5ec1","article-title":"Sphingosine 1-phosphate (S1P): physiology and the effects of S1P receptor modulation.","volume":"76","author":"Hla","year":"2011","journal-title":"Neurology"},{"key":"R43-20260218","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.bbalip.2010.12.005","article-title":"Heterogeneous sphingosine-1-phosphate lyase gene expression and its regulatory mechanism in human lung cancer cell lines.","volume":"1811","author":"Ito","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"R44-20260218","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1172\/JCI90171","article-title":"Sphingosine-1-phosphate lyase mutations cause primary adrenal insufficiency and steroid-resistant nephrotic syndrome.","volume":"127","author":"Prasad","year":"2017","journal-title":"J Clin Invest"},{"key":"R45-20260218","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1172\/JCI12450","article-title":"Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement.","volume":"108","author":"Garcia","year":"2001","journal-title":"J Clin Invest"},{"key":"R46-20260218","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.chemphyslip.2015.10.004","article-title":"Pulmonary endothelial cell barrier enhancement by novel FTY720 analogs: methoxy-FTY720, fluoro-FTY720, and beta-glucuronide-FTY720.","volume":"194","author":"Camp","year":"2016","journal-title":"Chem Phys Lipids"},{"key":"R47-20260218","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1183\/09031936.00047810","article-title":"FTY720-induced human pulmonary endothelial barrier enhancement is mediated by c-Abl.","volume":"38","author":"Wang","year":"2011","journal-title":"Eur Respir J"},{"key":"R48-20260218","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1007\/s10620-010-1421-0","article-title":"Sphingosine-1-phosphate regulates the expression of adherens junction protein E-cadherin and enhances intestinal epithelial cell barrier function.","volume":"56","author":"Greenspon","year":"2011","journal-title":"Dig Dis Sci"},{"key":"R49-20260218","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/s41419-021-03848-9","article-title":"Sgpl1 deletion elevates S1P levels, contributing to NPR2 inactivity and p21 expression that block germ cell development.","volume":"12","author":"Yuan","year":"2021","journal-title":"Cell Death Dis"},{"key":"R50-20260218","doi-asserted-by":"crossref","first-page":"10880","DOI":"10.1074\/jbc.M109.081489","article-title":"Sphingosine 1-phosphate lyase deficiency disrupts lipid homeostasis in liver.","volume":"285","author":"Bektas","year":"2010","journal-title":"J Biol Chem"},{"key":"R51-20260218","doi-asserted-by":"crossref","first-page":"4292","DOI":"10.4049\/jimmunol.0901724","article-title":"Discontinued postnatal thymocyte development in sphingosine 1-phosphate-lyase-deficient mice.","volume":"183","author":"Weber","year":"2009","journal-title":"J Immunol"},{"key":"R52-20260218","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1146\/annurev-immunol-081022-021207","article-title":"Structural mechanisms of NLRP3 inflammasome assembly and activation.","volume":"41","author":"Fu","year":"2023","journal-title":"Annu Rev Immunol"},{"key":"R53-20260218","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.tibs.2022.10.002","article-title":"The NLRP3 inflammasome: activation and regulation.","volume":"48","author":"Xu","year":"2023","journal-title":"Trends Biochem Sci"},{"key":"R54-20260218","doi-asserted-by":"crossref","first-page":"1109938","DOI":"10.3389\/fimmu.2022.1109938","article-title":"The mechanism of NLRP3 inflammasome activation and its pharmacological inhibitors.","volume":"13","author":"Zhan","year":"2022","journal-title":"Front Immunol"},{"key":"R55-20260218","doi-asserted-by":"crossref","first-page":"6119","DOI":"10.4049\/jimmunol.1002843","article-title":"Serum amyloid A activates the NLRP3 inflammasome via P2X7 receptor and a cathepsin B-sensitive pathway.","volume":"186","author":"Niemi","year":"2011","journal-title":"J Immunol"},{"key":"R56-20260218","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13024-016-0088-1","article-title":"The NLRP3 and NLRP1 inflammasomes are activated in Alzheimer\u2019s disease.","volume":"11","author":"Saresella","year":"2016","journal-title":"Mol Neurodegener"},{"key":"R57-20260218","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3233\/VES-1999-9206","article-title":"Comparison of two head autorotation tests.","volume":"9","author":"Hirvonen","year":"1999","journal-title":"J Vestib Res"},{"key":"R58-20260218","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1001\/jamacardio.2025.2948","article-title":"Transthyretin cardiac amyloidosis in older black and hispanic individuals with heart failure.","volume":"10","author":"Ruberg","year":"2025","journal-title":"JAMA Cardiol"},{"key":"R59-20260218","doi-asserted-by":"crossref","first-page":"28860","DOI":"10.1021\/jacs.5c06205","article-title":"Catalytic photooxygenation demonstrates therapeutic efficacy in transthyretin amyloidosis.","volume":"147","author":"Yamane","year":"2025","journal-title":"J Am Chem Soc"},{"key":"R60-20260218","doi-asserted-by":"crossref","first-page":"1666318","DOI":"10.3389\/fneur.2025.1666318","article-title":"Monitoring patients and asymptomatic carriers with hereditary transthyretin amyloidosis: regional protocol of Emilia-Romagna ATTR working group.","volume":"16","author":"Guaraldi","year":"2025","journal-title":"Front Neurol"},{"key":"R61-20260218","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1002\/ajmg.a.62956","article-title":"Congenital adrenal calcifications as the first clinical indication of sphingosine lyase insufficiency syndrome: a case report and review of the literature.","volume":"188","author":"Ron","year":"2022","journal-title":"Am J Med Genet A"},{"key":"R62-20260218","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.24953\/turkjped.2022.187","article-title":"Novel sphingosine-1-phosphate lyase mutation causes multisystemic diseases: case report.","volume":"65","author":"Buyukyilmaz","year":"2023","journal-title":"Turk J Pediatr"},{"key":"R63-20260218","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy.","volume":"392","author":"Fontana","year":"2025","journal-title":"N Engl J Med"},{"key":"R64-20260218","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy.","volume":"390","author":"Gillmore","year":"2024","journal-title":"N Engl J Med"},{"key":"R65-20260218","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","article-title":"Patisiran treatment in patients with transthyretin cardiac amyloidosis.","volume":"389","author":"Maurer","year":"2023","journal-title":"N Engl J Med"},{"key":"R66-20260218","doi-asserted-by":"crossref","first-page":"167820","DOI":"10.1016\/j.bbadis.2025.167820","article-title":"An unusual phenotype of hereditary AApoAI amyloidosis caused by a novel Asp20Tyr substitution is linked to pH-dependent aggregation of apolipoprotein A-I.","volume":"1871","author":"Prokaeva","year":"2025","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"R67-20260218","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/13506129.2025.2462992","article-title":"Global patterns of amyloid typing: results of a survey by the International Society of Amyloidosis (ISA).","volume":"32","author":"Naiki","year":"2025","journal-title":"Amyloid"},{"key":"R68-20260218","doi-asserted-by":"crossref","first-page":"106290","DOI":"10.1016\/j.jsbmb.2023.106290","article-title":"Selective vitamins as potential options for dietary therapeutic interventions: in silico and in vitro insights from mutant C terminal fragment of FGA.","volume":"230","author":"Pande","year":"2023","journal-title":"J Steroid Biochem Mol Biol"},{"key":"R69-20260218","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1053\/j.ajkd.2020.02.445","article-title":"Organ transplantation in hereditary fibrinogen A alpha-chain amyloidosis: a case series of French patients.","volume":"76","author":"Meyer","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"R70-20260218","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/13506129.2016.1257986","article-title":"Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines.","volume":"23","author":"Sipe","year":"2016","journal-title":"Amyloid"},{"key":"R71-20260218","doi-asserted-by":"crossref","first-page":"122534","DOI":"10.1016\/j.lfs.2024.122534","article-title":"GT-11 impairs insulin signaling through modulation of sphingolipid metabolism in C2C12 myotubes.","volume":"342","author":"Rustamov","year":"2024","journal-title":"Life Sci"},{"key":"R72-20260218","doi-asserted-by":"crossref","first-page":"725","DOI":"10.31557\/APJCP.2024.25.3.725","article-title":"A crosstalk between the receptor tyrosine kinase-like orphan receptors ROR1\/2 and S1P signaling pathways in lung cancer.","volume":"25","author":"Nema","year":"2024","journal-title":"Asian Pac J Cancer Prev"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000046653","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T17:01:52Z","timestamp":1771434112000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000046653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,2]]},"references-count":72,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000046653","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,2]]},"assertion":[{"value":"2025-06-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-12","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}